



**Date: 2 October 2019**

**Sydney, Australia**

ASX Limited  
20 Bridge Street  
SYDNEY NSW 2000

**Interview: The LuPIN trial with Veyonda® in prostate cancer**

---

**Sydney, 2 October 2019:**

Noxopharm (ASX: NOX) presents a Finance News Network (FNN) interview with its Executive Chairman and Founder, Dr Graham Kelly, following publication of further encouraging interim clinical data from the LuPIN trial.

<https://www.finnewsnetwork.com.au/MediaCenter/MediaCenterMobile.aspx?Site=FNN1659>

The interview will also be found on the Noxopharm website:

<https://www.noxopharm.com/site/investors/presentations>

---

**About Noxopharm**

Noxopharm is a clinical-stage Australian drug development company with offices in Sydney and New York. The Company has a primary focus on the development of Veyonda® and is the major shareholder in Nyrada Inc, a spin-off company developing a pipeline of non-oncology drugs.

[www.noxopharm.com](http://www.noxopharm.com)

**Investor & Corporate Enquiries:**

**Media Contact Australia**

Prue Kelly  
M: 0459 022 445  
E: [info@noxopharm.com](mailto:info@noxopharm.com)

**Company Secretary:**

David Franks  
T: +61 2 9299 9690  
E: [David.Franks@atomicgroup.com.au](mailto:David.Franks@atomicgroup.com.au)

**Media Contact USA:**

Frank de Maria  
Purposeful Communications  
T: +1 347 647 0284  
E: [frank.demaria@purposefulcommunications.com](mailto:frank.demaria@purposefulcommunications.com)

**Forward Looking Statements**

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement. No representation, warranty or assurance (express or implied) is given or made by Noxopharm that the forward-looking statements contained in this announcement are accurate and undue reliance should not be placed upon such statements.